Latvia vs State of Palestine: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Latvia
0.0%
in 2024
State of Palestine
0.0%
in 2024
Latvia rank
167th
State of Palestine rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Latvia
- State of Palestine
How they compare
Latvia currently reports 0.0% against 0.0% in State of Palestine, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was State of Palestine ahead.
Latvia ranks 167th and State of Palestine ranks 167th of 246 countries.
Latvia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latvia | State of Palestine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.0% | 0.0% | Latvia |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Latvia or State of Palestine?
- Latvia, at 0.0% against 0.0% in State of Palestine as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Latvia and State of Palestine?
- 0.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and State of Palestine?
- 10 years are reported by both, from 2015 to 2024.
- How do Latvia and State of Palestine rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Latvia ranks 167th and State of Palestine ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.